371 related articles for article (PubMed ID: 32993828)
1. Understanding how geographic, demographic and treatment history impact health outcomes of patients with multi-drug-resistant tuberculosis in Pakistan, 2014-2017.
Iqbal F; Defer MK; Latif A; Hadi H
Epidemiol Infect; 2020 Sep; 148():e253. PubMed ID: 32993828
[TBL] [Abstract][Full Text] [Related]
2. Fighting the tuberculosis epidemic in the Western Pacific region: current situation and challenges ahead.
van Maaren PJ
Kekkaku; 2010 Jan; 85(1):9-16. PubMed ID: 20143671
[TBL] [Abstract][Full Text] [Related]
3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
4. Multidrug-resistant tuberculosis in Rawalpindi, Pakistan.
Khurram M; Khaar HT; Fahim M
J Infect Dev Ctries; 2012 Jan; 6(1):29-32. PubMed ID: 22240425
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
[TBL] [Abstract][Full Text] [Related]
6. [Multidrug resistant tuberculosis in Romania in the last years (2004-2007)--an extremely important social phenomenon].
Marica C; Didilescu C; Chiotan D; Galie N; Tănăsescu M; Popescu-Hagen M; Popa M
Pneumologia; 2008; 57(4):195-200. PubMed ID: 19186681
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
[TBL] [Abstract][Full Text] [Related]
9. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
[TBL] [Abstract][Full Text] [Related]
10. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
11. Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan.
Javaid A; Hasan R; Zafar A; Chaudry MA; Qayyum S; Qadeer E; Shaheen Z; Agha N; Rizvi N; Afridi MZ; Chima MK; Khan AR; Ghafoor A; Khan S; Awan SR; Akhtar S; Choudry K; Iqbal ZH; Ansarie M; Ahmad N
Int J Tuberc Lung Dis; 2017 Mar; 21(3):303-308. PubMed ID: 28225340
[TBL] [Abstract][Full Text] [Related]
12. Multidrug-resistant tuberculosis in South Korea: a retrospective analysis of national registry data in 2011-2015.
Lee M; Han J; Kim YR; Kwak N; Kim JH; Park O; Shin S; Moon HS; Kim HJ; Jang MJ; Yim JJ
Int J Tuberc Lung Dis; 2019 Jul; 23(7):850-857. PubMed ID: 31439118
[No Abstract] [Full Text] [Related]
13. Multi-drug resistant tuberculosis burden and risk factors: an update.
Marahatta SB
Kathmandu Univ Med J (KUMJ); 2010; 8(29):116-25. PubMed ID: 21209520
[TBL] [Abstract][Full Text] [Related]
14. Editorial: Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis.
Parums DV
Med Sci Monit; 2021 Aug; 27():e934292. PubMed ID: 34366429
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
16. [Drug resistant tuberculosis].
Zwolska Z; Augustynowicz-Kopeć E
Pol Merkur Lekarski; 2011 May; 30(179):362-6. PubMed ID: 21675144
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of treating multidrug-resistant tuberculosis.
Resch SC; Salomon JA; Murray M; Weinstein MC
PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
[TBL] [Abstract][Full Text] [Related]
18. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
[TBL] [Abstract][Full Text] [Related]
19. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
Centers for Disease Control and Prevention (CDC)
MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
